Questcor Pharmaceuticals (NASDAQ:QCOR)

CAPS Rating: 2 out of 5

A pharmaceutical company that focuses on novel therapeutics for the treatment of diseases and disorders of the central nervous system.

Results 1 - 20 of 73 : 1 2 3 4 Next »

Recs

0
Member Avatar justiny (95.21) Submitted: 3/24/2014 2:14:17 PM : Underperform Start Price: $60.02 QCOR Score: -27.60

Regulatory scrutiny, while I'm not sure, where there is smoke, there may be fire.

Recs

0
Member Avatar TrackMagicFormul (92.63) Submitted: 3/19/2014 2:39:56 PM : Outperform Start Price: $79.11 QCOR Score: -3.42

Investors should consider selling puts. You can achieve some very high annualized returns at strikes significantly below the current price. e.g.

Jul 14 $50 strike at $5.00 has 29% discount and 29% annualized return.

Recs

0
Member Avatar pbookidis (< 20) Submitted: 3/1/2014 6:21:28 PM : Outperform Start Price: $59.90 QCOR Score: +27.54

Citron has been it's attack dog for some time and recently stated that Qcor's Acthar drug is a hoax.
I'm betting it is not and ultimately Qcr will prevail.

Recs

0
Member Avatar healthcarevalue (98.01) Submitted: 2/24/2014 4:54:52 PM : Outperform Start Price: $79.95 QCOR Score: -4.48

18 times earnings at present, however low debt and quite impressive price earnings ratio of over 90 percent.

Recs

0
Member Avatar Unborn (< 20) Submitted: 1/26/2014 2:31:07 PM : Outperform Start Price: $50.12 QCOR Score: +52.29

Rule #1 pick

Recs

0
Member Avatar modestus1 (< 20) Submitted: 1/16/2014 8:28:27 PM : Outperform Start Price: $61.56 QCOR Score: +23.76

Merger possible

Recs

0
Member Avatar GirlsUnder30 (96.41) Submitted: 12/24/2013 5:16:55 PM : Underperform Start Price: $78.20 QCOR Score: +2.79

This is a treatment drug and drugs of this class will suffer increasing scrutiny from the government in the future.

Recs

0
Member Avatar optionsmaster (40.96) Submitted: 12/20/2013 10:48:29 AM : Outperform Start Price: $51.67 QCOR Score: +46.20

Big time cash flow

Recs

0
Member Avatar nadda (< 20) Submitted: 12/10/2013 9:17:54 AM : Outperform Start Price: $51.12 QCOR Score: +47.54

growth stock

Recs

0
Member Avatar ruinas (28.00) Submitted: 11/26/2013 8:26:55 PM : Underperform Start Price: $56.19 QCOR Score: -33.89

hoped for new agents or purchased generic agenrts slow to produce yield

Recs

0
Member Avatar huddaman (97.35) Submitted: 11/8/2013 11:37:51 AM : Outperform Start Price: $58.38 QCOR Score: +26.73

Growth is astounding. Only reason I am a little skeptical is, the price they charge for their medicine is atrocious. It's almost a crime against humanity. I own in real life, but I won't be upset if they were forced to cut down their med cost at my expense (shareholder). I rather if someone gets cured or treated then fill my own pocketbook. But it still doesn't stop my from investing. It's not like if I refuse to buy their stock, they will go out of business. In fact, if everyone did that, a PE would buy it and raise prices even further.

Recs

0
Member Avatar grankh (87.50) Submitted: 10/20/2013 1:09:31 AM : Outperform Start Price: $65.68 QCOR Score: +8.40

This is another of my real-life holdings.

Since 2010, sales have gone up 96% per year and EPS has gone up 114% per year. Amazing growth. The profit margin has also grown since 2010, as has earned-on-equity. To top all that off, the company has NO DEBT! The current P/E is very reasonable for such a fast-growing company, at around 18, which is below the P/E's it traded for over the past 4 years. The PEG ratio is also low. And as an icing on the cake, the company instituted a dividend last year, and in 2012 paid a decent 2.3% yield on a 13% payout ratio. Not a big yield, but positive that they instituted one and also, since the payout ratio is so low, there is plenty of room to grow the dividend if the company elects to do so.

I am looking for this stock to grow to $140 or so in the next 5 years, or more than double its current price. With the dividend, this would give me a 17% per year gain, and that is assuming that the growth rate slows to 1/4 what it has done over the past few years. If it keeps growing at recent rates, then it should hit that target price in less than half of my 5 year forecast. So this is a stock I am pretty excited about. We'll have to see if my expectations pay out for me.

Recs

0
Member Avatar TMFTypeoh (78.76) Submitted: 10/19/2013 1:05:18 PM : Outperform Start Price: $63.72 QCOR Score: +13.91

Wow the numbers look terrific. I don't fully understand the business just yet, but what I've read so far look really good. If analyst growth is to be believed, lots of upside from here.

Recs

0
Member Avatar pensiveone (78.34) Submitted: 9/30/2013 9:17:19 PM : Outperform Start Price: $57.73 QCOR Score: +22.43

Numerous indications just hitting their stride, Synacthen sales into the US and Acthar sales interenationally will propel sales for years to come.

Recs

0
Member Avatar hobiecat52 (< 20) Submitted: 9/19/2013 3:42:25 AM : Outperform Start Price: $64.71 QCOR Score: +11.50

Very good recent earnings growth coupled with a reasonable valuation.

Recs

0
Member Avatar stkjunky (< 20) Submitted: 7/31/2013 1:53:03 PM : Outperform Start Price: $66.01 QCOR Score: +6.25

The fundamentals on this company are very good. But, the price is getting a little ahead of the earnings.
Management seems good, a big plus.

Recs

0
Member Avatar 2trpop (94.13) Submitted: 7/25/2013 2:44:11 PM : Outperform Start Price: $46.63 QCOR Score: +54.49

fstg experiment

Recs

0
Member Avatar Shapangus (< 20) Submitted: 6/20/2013 11:13:01 PM : Outperform Start Price: $44.24 QCOR Score: +57.20

Rheumatology scripts will increase and as Don Bailey said, each of them could be equal to current sales. 50 new reps hired by 1st quarter and are now trained and on the job.

Recs

0
Member Avatar manirg (41.06) Submitted: 6/14/2013 1:19:58 PM : Outperform Start Price: $45.15 QCOR Score: +56.14

very undervalued

Recs

0
Member Avatar Reddragyn (69.84) Submitted: 5/21/2013 5:50:46 AM : Outperform Start Price: $37.03 QCOR Score: +96.23

IMF

Results 1 - 20 of 73 : 1 2 3 4 Next »

Featured Broker Partners


Advertisement